Date: Wednesday, 05.07.2006 -- Press release, Berlin, Germany and Seattle, WA, USA -- Epigenomics AG (Frankfurt, Prime Standard: ECX), a molecular diagnostics company developing tests based on DNA methylation, is presenting new clinical data on its colorectal cancer early detection marker in blood. The results indicate that, combined with a second proprietary marker, the test is also able to detect most polyps without many false positive results. Colon polyps are benign proliferations that can give rise to cancer. The risk is considerably high if they are greater than 1 cm in size. Their timely removal is therefore a major contribution to saving patients’ lives. Data were presented at the 8th World Congress on Gastrointestinal Cancer in Barcelona from June 28 to July 1.
